logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
D

David Belada

university hospital hradec kralove
H指数:32
被引数:7,836

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up

更正: Brentuximab vedotin联合化疗治疗一线系统性间变性大细胞淋巴瘤: 5年随访时ECHELON-2研究的亚组分析

Blood Cancer Journal
IF11.6
2026-01-280
OAAI
Eva Domingo-Domènech; Barbara Pro; Tim Illidge; Steven Horwitz; Lorenz Trumper; Swami Iyer; Ranjana Advani; Nancy L. Bartlett; Jacob Haaber Christensen; Won-Seog Kim; Tatyana Feldman; Ilseung Choi; Giuseppe Gritti; David Belada; Andrei Shustov; Arpad Illes; Pier Luigi Zinzani; Andreas Hüttmann; Marek Trneny; Steven Le Gouill; Deepa Jagadeesh; Jonathan W. Friedberg; Meredith Little; Cassie Dong; Michelle Fanale; Keenan Fenton; Kerry J. Savage
ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +/− lenalidomide and predicts outcome in diffuse large B-cell lymphoma: results from the phase 1b First-MIND study

ctDNA动力学证明了tafasitamab + R-CHOP +/- lenalidomide的快速治疗反应，并能预测弥漫性大B细胞淋巴瘤的结局：First-MIND 1b期研究结果

Leukemia
IF13.4
2025-10-270
OA
Mouhamad Khouja; Britta Kehden; Derek Blair; Christian Kuffer; Steve Wagner; Tim Versteegen; Philipp Nakov; Monika Brüggemann; Claudia Baldus; David Belada; Grzegorz S. Nowakowski; Anke Schilhabel; Nikos Darzentas; Christiane Pott
Long-Term Real-World Outcomes of Primary CNS Lymphoma Patients Treated With MATRix Regimen Are Similar to IELSG32 Trial Results

接受MATRix方案治疗的原发性中枢神经系统淋巴瘤患者的长期真实世界结果与IELSG32试验结果相似。

Hematological Oncology
IF3.9
2025-10-180
OAAI
Prokop Vodicka; Andrea Janikova; David Belada; Veronika Hanackova; Heidi Mocikova; Juraj Duras; Katerina Steinerova; Katerina Benesova; Eva Konirova; Tomas Prochazka; Kamila Polgarova; Michal Masar; Jitka Dlouha; Petra Blahovcova; Marek Trneny
Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma

固定疗程的Epcoritamab联合R2方案可改善复发或难治性滤泡性淋巴瘤患者的预后。

Blood
IF23.1
2025-09-100
OAAI
Lorenzo Falchi; Anna Sureda; Sirpa Leppä; Joost S.P. Vermaat; Marcel Nijland; Jacob Haaber Christensen; Sven de Vos; Harald Holte; Reid W. Merryman; Pieternella J. Lugtenburg; Pau Abrisqueta; Kim M. Linton; Gauri Sunkersett; Daniela Hoehn; Ali Rana; Aqeel Abbas; Jennifer Marek; Yi Hao; Andrew J. Steele; Christopher Morehouse; Martin Hutchings; David Belada
Association of PET4 Response With Outcomes of BV-CHP vs CHOP in the ECHELON-2 Trial in CD30+ Peripheral T-cell Lymphoma

PET4反应与ECHELON-2试验中CD30+外周T细胞淋巴瘤患者接受BV-CHP vs CHOP治疗的结局相关性研究

Blood Advances
IF7.1
2025-08-210
OAAI
Swaminathan Iyer; Neha Mehta-Shah; Ranjana Advani; Nancy L. Bartlett; Jacob H. Christensen; Franck Morschhauser; Eva Domingo-Domenech; Giuseppe Rossi; Won Seog Kim; Onder Alpdogan; Tatyana A. Feldman; Vincent Camus; Giuseppe Gritti; Pier Luigi Zinzani; David Belada; Jiri Mayer; Ilseung Choi; June-Won Cheong; Evelyn Rustia; Keenan Fenton
Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up

brentuximab vedotin联合化疗用于一线系统性间变性大细胞淋巴瘤的治疗：ECHELON-2研究5年随访的亚组分析

Blood Cancer Journal
IF11.6
2025-08-010
OAAI
Eva Domingo-Domènech; Barbara Pro; Tim Illidge; Steven Horwitz; Lorenz Trumper; Swami Iyer; Ranjana Advani; Nancy L. Bartlett; Jacob Haaber Christensen; Won-Seog Kim; Tatyana Feldman; Ilseung Choi; Giuseppe Gritti; David Belada; Andrei Shustov; Arpad Illes; Pier Luigi Zinzani; Andreas Hüttmann; Marek Trneny; Steven Le Gouill; Deepa Jagadeesh; Jonathan W. Friedberg; Meredith Little; Cassie Dong; Michelle Fanale; Keenan Fenton; Kerry J. Savage
Efficacy and safety of rituximab biosimilar (DRL_RI) versus MabThera® in low-tumor-burden follicular lymphoma: the FLINTER study

利妥昔单抗生物类似药（DRL_RI）与MabThera®在低肿瘤负荷滤泡性淋巴瘤中的有效性和安全性：FLINTER研究

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
IF4.2
2025-05-240
OA
Narendra Maharaj; Dharma Rao Uppada; Anand Eswaraiah; Ranjith Kakkattu; Pramod Reddy; Volha A. Kalenik; David Belada; Ana Oliveira Ramos; Jin Seok Kim; Yauheni V. Baranau
Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial

Epcoritamab联合GemOx在移植不合格的复发/难治性DLBCL中的应用：EPCORE NHL-2试验的结果

BLOOD
IF23.1
2025-01-103
OA
Brody, Joshua D.; Jorgensen, Judit; Belada, David; Costello, Regis; Trneny, Marek; Vitolo, Umberto; Lewis, David John; Karimi, Yasmin H.; Sureda, Anna; Andre, Marc; Wahlin, Bjoern E.; Lugtenburg, Pieternella J.; Jiang, Tony; Karagoz, Kubra; Steele, Andrew J.; Abbas, Aqeel; Wang, Liwei; Risum, Malene; Cordoba, Raul
Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia
BLOOD ADVANCES
IF7.1
2024-03-283
OAAI
Tam, Constantine S.; Opat, Stephen; D'Sa, Shirley; Jurczak, Wojciech; Lee, Hui-Peng; Cull, Gavin; Owen, Roger G.; Marlton, Paula; Wahlin, Bjoern E.; Garcia-Sanz, Ramon; McCarthy, Helen; Mulligan, Stephen; Tedeschi, Alessandra; Castillo, Jorge J.; Czyz, Jaros law; De Larrea, Carlos Fernandez; Belada, David; Libby, Edward; Matous, Jeffrey; Motta, Marina; Siddiqi, Tanya; Tani, Monica; Trneny, Marek; Minnema, Monique C.; Buske, Christian; Leblond, Veronique; Treon, Steven P.; Trotman, Judith; Wu, Binghao; Yu, Yiling; Shen, Zhirong; Chan, Wai Y.; Schneider, Jingjing; Allewelt, Heather; Cohen, Aileen; Dimopoulos, Meletios A.
Effectiveness of tixagevimab/cilgavimab in patients with hematological malignancies as a pre-exposure prophylaxis to prevent severe COVID-19: a Czech retrospective multicenter study
ANNALS OF HEMATOLOGY
IF2.4
2023-12-142
OAAI
Demel, Ivo; Skopal, David; Safrankova, Eliska; Rozsivalova, Petra; Jindra, Pavel; Sramek, Jiri; Turkova, Adela; Vydra, Jan; Labska, Klara; Vedrova, Jana; Cernan, Martin; Szotkowski, Tomas; Mocikova, Heidi; Hynkova, Lenka; Susol, Ondrej; Kovacova, Ingrid; Belada, David; Hajek, Roman
Parsaclisib, a PI3Kd inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study

Parsaclisib，一种PI3Kd抑制剂，用于复发和难治性滤泡性淋巴瘤 (CITADEL-203): 一项2期研究

ECLINICALMEDICINE
IF10
2023-09-013
OAAI
Trneny, Marek; Avigdor, Abraham; Mckinney, Matthew S.; Paneesha, Shankara; Wahlin, Bjorn E.; Hrom, John S.; Cunningham, David; Morley, Nicholas; Canales, Miguel; Bastos-Oreiro, Mariana; Belada, David; Devizzi, Liliana; Zheng, Fred; Demarini, Douglas J.; Jiang, Wei; Jiang, Ping; Lynch, Ryan C.
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma
NEW ENGLAND JOURNAL OF MEDICINE
IF78.5
2022-06-30101
OA
Wang, Michael L.; Jurczak, Wojciech; Jerkeman, Mats; Trotman, Judith; Zinzani, Pier L.; Belada, David; Boccomini, Carola; Flinn, Ian W.; Giri, Pratyush; Goy, Andre; Hamlin, Paul A.; Hermine, Olivier; Hernandez-Rivas, Jose-Angel; Hong, Xiaonan; Kim, Seok Jin; Lewis, David; Mishima, Yuko; Ozcan, Muhit; Perini, Guilherme F.; Pocock, Christopher; Song, Yuqin; Spurgeon, Stephen E.; Storring, John M.; Walewski, Jan; Zhu, Jun; Qin, Rui; Henninger, Todd; Deshpande, Sanjay; Howes, Angela; Le Gouill, Steven; Dreyling, Martin
The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma

ECHELON-2试验: brentuximab vedotin联合化疗治疗CD30-positive外周T细胞淋巴瘤的随机III期研究的5年结果

ANNALS OF ONCOLOGY
IF65.4
2022-03-01128
OAAI
Horwitz, S.; O'Connor, O. A.; Pro, B.; Trumper, L.; Iyer, S.; Advani, R.; Bartlett, N. L.; Christensen, J. H.; Morschhauser, F.; Domingo-Domenech, E.; Rossi, G.; Kim, W. S.; Feldman, T.; Menne, T.; Belada, D.; Illes, A.; Tobinai, K.; Tsukasaki, K.; Yeh, S-P; Shustov, A.; Huettmann, A.; Savage, K. J.; Yuen, S.; Zinzani, P. L.; Miao, H.; Bunn, V; Fenton, K.; Fanale, M.; Puhlmann, M.; Illidge, T.

研究方向

暂未获取到该数据
M
Marek Trněný
H 指数:68论文数:757被引数:2.5万
H
Heidi Móciková
H 指数:17论文数:182被引数:2,087
A
Andrea Janíková
H 指数:25论文数:273被引数:1,827
V
Vít Procházka
H 指数:18论文数:181被引数:1,508
R
Robert Pytlík
H 指数:28论文数:184被引数:2,321
A
Alice Šýkorová
H 指数:8论文数:85被引数:220
J
Juraj Ďuraš
H 指数:10论文数:76被引数:390
P
Pier Luigi Zinzani
H 指数:117论文数:1,841被引数:6.1万
P
Pavel Klener
H 指数:31论文数:263被引数:2,864
M
Martin Šimkovič
H 指数:23论文数:161被引数:3,835